Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis

Surgical Infections

Volumn 5, Issue 3, 2004, Pages 253-259

  Fry, Donald E ^a   Beilman, Gregory ^b   Johnson, Steven ^c   Williams, Mark D ^d   Rodman, George ^e   Booth, Frank V ^d   Bates, Becky M ^d   McCollam, Jill Shwed ^d   Lowry, Stephen F ^f   Awad, Samir ^g   Barie, Philip S ^h   Cheadle, William ⁱ   Fink, Mitchell ^j   Ford, Henri ^k  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^k CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; FRESH FROZEN PLASMA; PLACEBO;

ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CLINICAL OBSERVATION; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INFUSION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATALITY; FISHER EXACT TEST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; STATISTICAL ANALYSIS; SURGICAL PATIENT; SURGICAL TECHNIQUE; THROMBOCYTE TRANSFUSION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVALUATION STUDIES; FEMALE; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN C; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEPSIS; SEVERITY OF ILLNESS INDEX; SURGICAL PROCEDURES, OPERATIVE; SURGICAL WOUND INFECTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 7744236412     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2004.5.253     Document Type: Article

References (14)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
2. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997;25:1095-1100.
3. Crowther MA, Marshall JC. Continuing challenges of sepsis research. JAMA 2001;286:1894-1896.
4. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
5. Lovenox. BN0. Package Insert. Aventis Pharmaceuticals Inc., 2004.
6. Institute for Clinical Systems Improvement (ICSI). Venous Thromboembolism Prophylaxis for Surgical/Trauma Patients. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI), 2003.
7. Barie PS, Williams MD, McCollam JS, et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212-220.
8. Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 2003;31:2291-2301.
9. Savani D, Boylen T. Clinical outcomes and adverse effects of patients treated with drotrecogin alfa. Crit Care Med 2003;30(suppl):A104.
10. Wong-Beringer A, Liao C, Nguyen M, et al. Applying patient selection criteria for drotrecogin alfa therapy in practice. Am J Health Syst Pharm 2003; 60:1345-1352.
11. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878.
12. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts - Blood transfusion. N Engl J Med 1999;340:438-447.
13. Goodnough LT, Brecher ME, Kanter MH et al. Transfusion medicine. Second of two parts - Blood conservation. N Engl J Med 1999;340:525-533.
14. Wheeler APM, Doig CM, Wright TM, et al. Baseline characteristics and survival of adult severe sepsis patients treated with drotrecogin alfa (activated) in a global, single-arm, open-label trial (ENHANCE) [Abstract]. Chest 2003;124:91S-92S.